We are pleased to invite you to a webinar with excellent speakers, focusing on von Willebrand disease (VWD). We arrange this educational symposium for all HCPs in the Nordics, as a part of Veyvondi (vonikog alfa) being reimbursed in Finland.

The meeting, chaired by Prof. Riitta Lassila, together with expert speakers Dr. Maria Bruzelius and Hon. Prof. Peter Turecek, will aim to delve into the challenges of diagnosing VWD, discussing treatment and patient management, presenting vonikog alfa clinical data as well as enabling discussions on prophylactic treatment through case examples.

Welcome!

Date

March 12th 2025, 15:00–16:15 (CET)

Register here

Speakers

Riitta Lassila, MD, PhD, is the Director of the Unit of Coagulation Disorders at Helsinki University Central Hospital and a Professor of Coagulation Medicine at Helsinki University. Riitta specializes in platelet function and procoagulant activity.

Maria Bruzelius, MD, PhD, is a Senior Consultant at Karolinska University Hospital and Ass. Professor at Karolinska Institutet, Sweden. Maria has a strong background in clinical practice, research, and education, and is actively engaged in ongoing clinical trials.

Peter L. Turecek, is a lecturer at the University of Vienna and an honorary professor at the University of Applied Sciences in Krems, Austria. He has held various management positions in the pharmaceutical industry since 1989, including at Baxalta Innovations GmbH, a Takeda company. Dr. Turecek has co-founded startups in biotechnology and AI, holds a doctorate in biochemistry, and has over 1,400 patents and 150 publications. He acts as a scientific consultant and represents biopharma to international regulatory authorities.

Bild	Bild	Bild
Riitta Lassila	Maria Bruzelius	Peter L. Turecek

Agenda

15.00–15.05  Welcome and introduction, Takeda and Prof. Riitta Lassila

15.05–15.25 Overview on von Willebrand disease – symptoms, diagnosis, types, treatment options, Prof. Riitta Lassila

15.25–15.45  Vonikog alfa clinical data and mode of action, Hon. Prof. Peter L. Turecek

15.45–16.05  Treatment decisions and patient management, when to consider prophylactic treatment in von Willebrand patients, Dr. Maria Bruzelius

16:05–16:15 Questions and discussion, All

16.15 Closing remarks, Prof. Riitta Lassila

An educational symposium for healthcare professionals, initiated, organized and funded by Takeda.

Takeda stands for the venue and pays for the lecturer fees.

For more information, please contact:

Cajsa Webber Hasselbring
Brand and Customer Manager
Mobile +46-705 38 51 00
Email: cajsa.hasselbring@takeda.com